SOURCE: Burrill & Company
SAN FRANCISCO, CA--(Marketwire - Jun 26, 2012) - Burrill & Company today announced that David Wetherell, a veteran entrepreneur and venture capitalist who joined the firm at the start of 2012, has been named President and COO of Burrill's Healthcare Venture and related Private Equity Funds.
"David has been a valuable addition to the firm and we welcome the additional contribution he will make in this expanded role," says G. Steven Burrill, CEO of Burrill & Company, a diversified global financial services firm focused on the life sciences industry. Investment Committee decisions for each Burrill fund will continue to be made by the Managing Directors responsible for each fund.
Wetherell has spent 20 years as a CEO in high-tech, as well as 17 years in venture capital, the last seven of which have been dedicated to biotech and life sciences. From 1986 to 2006, he served as both CEO and, later, chairman of CMGI, where he helped build the company from $3 million in annual revenues to more than $1 billion and started the first venture capital firm focused on the Internet, @Ventures. In 2003, due to the mapping of the human genome and demographic trends, Wetherell turned his attention to the life sciences.
In 2005, he started GBP Capital, a venture capital company focused exclusively on leading edge life sciences. Wetherell has received numerous awards, including Ernst & Young's New England Entrepreneur of the Year in 2000 and recognition as one of Money Magazine's Top 25 investors. He obtained his B.A. in Mathematics from Ohio Wesleyan University and an honorary doctorate from Bryant University. He currently serves as chairman of Lentigen and sits on the boards of numerous other companies, including Flexible Stenting Solutions, HyperMed, Quintess, and Whiteglove Health.
About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: